Last reviewed · How we verify
Tramadol Hydrochloride Plus Acetaminophen
At a glance
| Generic name | Tramadol Hydrochloride Plus Acetaminophen |
|---|---|
| Also known as | JNS013 |
| Sponsor | Janssen Korea, Ltd., Korea |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Analgesic Efficacy and Obstetric Effects of Tramadol, Paracetamol and Placebo in Active Labor (PHASE4)
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Impact of Opioid Avoidance Protocol for ACL Reconstruction
- PROUD Study - Preventing Opioid Use Disorders (PHASE4)
- Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee (PHASE2)
- Multimodal Analgesia in Shoulder Arthroplasty (PHASE3)
- Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar (PHASE4)
- Oral Use of Dexketoprofen/Tramadol for Acute Postoperative Pain in Total Hip Replacement With a Direct Anterior Approach. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: